

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Innovax-ILT concentrate and solvent for suspension for injection for chickens

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose (0.2 ml) of reconstituted vaccine contains:

### Active substance:

Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus:  $10^{3.1} - 10^{4.1}$  PFU<sup>1</sup>.

<sup>1</sup> PFU: plaque forming units.

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Concentrate and solvent for suspension for injection.

Cell concentrate: off-red to red cell concentrate.

Solvent: clear, red solution.

## 4. CLINICAL PARTICULARS

### 4.1 Target species

Chickens.

### 4.2 Indications for use, specifying the target species

For active immunisation of one-day-old chicks to reduce mortality, clinical signs and lesions due to infection with avian infectious laryngotracheitis (ILT) virus and Marek's disease (MD) virus.

Onset of immunity:      ILT: 4 weeks,  
                                 MD: 9 days.

Duration of immunity:   ILT: 60 weeks,  
                                 MD: entire risk period.

### 4.3 Contraindications

None.

### 4.4 Special warnings for each target species

Vaccinate healthy animals only.

### 4.5 Special precautions for use

#### Special precautions for use in animals

As this is a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys. Safety trials have shown that the strain is safe for turkeys. However, precautionary measures

have to be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys.

During subcutaneous vaccination, care should be taken to prevent damage of the blood vessels in the neck of the chickens.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

The handling of liquid nitrogen should take place in a well-ventilated area.

Innovax-ILT is a virus suspension packed in glass ampoules and stored in liquid nitrogen. Before withdrawing ampoules from the liquid nitrogen canister, protective equipment consisting of gloves, long sleeves and a facemask and goggles should be worn. In case of an accident to prevent serious wounds by either the liquid nitrogen or the ampoules when removing an ampoule from the canister, hold palm of gloved hand away from body and face. Care should be exercised to prevent contaminating your hands, eyes and clothing with the ampoule content. CAUTION: Ampoules have been known to explode on sudden temperature changes. Do not thaw in hot or ice-cold water. For this reason, thaw the ampoules in clean water at 25–27 °C. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

None known.

#### **4.7 Use during pregnancy, lactation or lay**

No information is available on the use in future breeding birds.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Safety and efficacy data are available which demonstrate that Innovax-ILT can be mixed in the same solvent and administered with Nobilis Rismavac in Member States where this vaccine is authorized. When Innovax-ILT is mixed with Nobilis Rismavac the development of immunity towards ILT may be delayed in animals with maternally derived antibodies.

For this mixed use, an onset of immunity of 5 days has been demonstrated for MD.

Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day, but not mixed with, Nobilis ND Clone 30 or Nobilis ND C2.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

#### **4.9 Amounts to be administered and administration route**

Subcutaneous use.

##### Preparation of the vaccine:

Disinfect vaccinating equipment by boiling in water for 20 minutes or by autoclaving (15 minutes at 121 °C). Do not use chemical disinfectants.

The handling of liquid nitrogen should take place in a well-ventilated area.

1. Use solvent for cell associated poultry vaccines for reconstitution.

For subcutaneous use reconstitute the vaccine according to the table below:

<b>Solvent bag</b>	<b>Number of vaccine ampoules for subcutaneous use</b>
Bag of 400 ml solvent	1 ampoule containing 2000 doses
Bag of 800 ml solvent	2 ampoules containing 2000 doses
Bag of 800 ml solvent	1 ampoule containing 4000 doses

<b>Solvent bag</b>	<b>Number of vaccine ampoules for subcutaneous use</b>
Bag of 1200 ml solvent	3 ampoules containing 2000 doses
Bag of 1600 ml solvent	4 ampoules containing 2000 doses
Bag of 1600 ml solvent	2 ampoules containing 4000 doses

When this product is mixed with Nobilis Rismavac, both should be diluted in the same solvent bag in the same way (400 ml of solvent for each 2,000 doses of both products or 800 ml of solvent for each 4,000 doses of both products).

The solvent must be clear, red coloured, without sediment and at room temperature (15–25 °C) at the time of mixing.

2. Preparation of the vaccine shall be planned before the ampoules are taken from the liquid nitrogen and the exact amount of vaccine ampoules and amount of solvent needed shall be calculated first. There is no information available on the number of doses on the ampoules once they are removed from the cane, so special care has to be taken to ensure that the mix-ups of ampoules with different number of doses is avoided and the correct solvent is used.
3. Before withdrawing the ampoules from the liquid nitrogen container, protect hands with gloves, wear long sleeves and use a facemask or goggles. When removing an ampoule from the cane, hold in the palm of a gloved hand away from the body and the face.
4. When withdrawing a cane of ampoules from the canister in the liquid nitrogen container, expose only the ampoule(s) to be used immediately. It is recommended to handle a maximum of 5 ampoules (from one cane only) at a time. After removing the ampoule(s), the remaining ampoules should be put back immediately into the canister in the liquid nitrogen container.
5. The content of the ampoule(s) is thawed rapidly by immersing in clean water at 25–27 °C. Gently swirl the ampoule(s) to disperse the contents. It is important that the ampoule content, after being thawed, is mixed immediately into the solvent to protect the cells. Dry the ampoule, then break the ampoule at its neck and immediately proceed as described below.
6. Gently withdraw the contents of the ampoule into a sterile syringe, mounted with an 18 gauge needle.
7. Insert the needle through the stopper of the solvent bag and add slowly and gently the contents of the syringe to the solvent. Gently swirl and invert the bag to mix the vaccine. Withdraw a portion of the solvent into the syringe to rinse the ampoule. Remove the washing from the ampoule and inject it gently into the solvent bag. Remove the syringe and invert the bag (6–8 times) to mix the vaccine.
8. The vaccine is now ready for use.

After adding the content of the ampoule to the solvent, the ready to use product is a clear, red coloured suspension for injection.

#### Posology:

One single injection of 0.2 ml per chick at the age of one day, by the subcutaneous route.

#### Administration:

The vaccine is administered by subcutaneous injection in the neck. The bag of vaccine should be gently swirled frequently during vaccination to guarantee that the vaccine suspension remains homogenous and that the correct vaccine virus titre is administered (e.g. during long vaccination sessions).

#### Control of correct storage:

To allow a check on correct storage and transport the ampoules are placed upside down in the liquid nitrogen containers. If frozen content is situated in the tip of the ampoule this indicates that the content has been thawed and must not be used.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

No symptoms were observed after the administration of a 10-fold dose of vaccine.

#### **4.11 Withdrawal period(s)**

Zero days.

### **5. IMMUNOLOGICAL PROPERTIES**

Pharmacotherapeutic group: immunologicals for Aves, live viral vaccines for domestic fowls.  
ATCvet code: QI01AD.

The vaccine is a cell-associated live recombinant turkey herpesvirus (HVT) expressing the gD and gI glycoproteins of infectious laryngotracheitis virus. The vaccine induces active immunity against infectious laryngotracheitis and Marek's disease in chickens.

### **6. PHARMACEUTICAL PARTICULARS**

#### **6.1 List of excipients**

Cell concentrate:

Bovine serum  
Basal medium  
Dimethyl sulfoxide

Solvent:

Sucrose  
Sodium chloride  
Disodium hydrogen phosphate dihydrate  
Phenolsulfonphthalein (Phenol red)  
Potassium dihydrogen phosphate  
Water for injections

#### **6.2 Major incompatibilities**

Do not mix with any other veterinary medicinal product except, Nobilis Rismavac and the solvent supplied for use with the veterinary medicinal product.

#### **6.3 Shelf life**

Shelf life of the cell concentrate as packaged for sale: 3 years.

Shelf life of the solvent (multilayer plastic bags) as packaged for sale: 3 years.

Shelf life after reconstitution according to directions: 2 hours at a temperature below 25 °C.

#### **6.4 Special precautions for storage**

Cell concentrate:

Store and transport frozen in liquid nitrogen (-196 °C).

Solvent:

Store below 30 °C.

Container:

Store liquid nitrogen container securely in upright position in a clean, dry and well-ventilated room separated from the hatching/chicken room in the hatchery.

#### **6.5 Nature and composition of immediate packaging**

Cell concentrate:

- One Type I glass ampoule of 2 ml containing 2,000 or 4,000 doses. Ampoules are stored on a cane and attached to the cane is a coloured clip displaying the dose (2,000 doses: salmon-pink coloured clip, and 4,000 doses: yellow coloured clip).

**Solvent:**

- One 400 ml multilayer plastic bag.
- One 800 ml multilayer plastic bag.
- One 1200 ml multilayer plastic bag.
- One 1600 ml multilayer plastic bag.

Not all pack sizes may be marketed.

## **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxtmeer  
THE NETHERLANDS

## **8. MARKETING AUTHORISATION NUMBER(S)**

EU/2/15/182/001-002

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 03/07/2015

Date of last renewal: 24/04/2020

## **10. DATE OF REVISION OF THE TEXT**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

## **PROHIBITION OF SALE, SUPPLY AND/OR USE**

Any person intending to manufacture, import, possess, sell, supply and use this veterinary medicinal product must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.

## **ANNEX II**

- A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCES AND  
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**
- D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING  
AUTHORISATION**

**A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND  
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer of the biological active substance

Intervet Inc.  
29160 Intervet Lane  
PO Box 318, Millsboro  
Delaware 19966-0318  
UNITED STATES OF AMERICA

Intervet International B.V.  
Ambachtstraat 2-6  
3732 CN De Bilt  
THE NETHERLANDS

Name and address of the manufacturer responsible for batch release

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxtmeer  
THE NETHERLANDS

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Veterinary medicinal product subject to prescription.

According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:

- a) the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
- b) the disease to which the product is intended to confer immunity is largely absent from the territory in question.

**C. STATEMENT OF THE MRLs**

The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009.

The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.

**D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING  
AUTHORISATION**

None.



**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**  
**AMPOULE**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Innovax-ILT

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

HVT/ILT-138

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

2,000

4,000

(number of doses per ampoule is presented on the colour coded clip attached to each cane containing the ampoule)

**4. ROUTE(S) OF ADMINISTRATION**

SC

**5. WITHDRAWAL PERIOD(S)**

**6. BATCH NUMBER**

Lot

**7. EXPIRY DATE**

EXP

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

MSD Animal Health Logo

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE****SOLVENT BAG****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Solvent for cell associated poultry vaccines

**2. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

400 ml  
800 ml  
1200 ml  
1600 ml

**3. ROUTE(S) OF ADMINISTRATION**

Read package leaflet before use.

**4. STORAGE CONDITIONS**

Store below 30 °C.

**5. BATCH NUMBER**

Lot

**6. EXPIRY DATE**

EXP

**7. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

## **B. PACKAGE LEAFLET**

**PACKAGE LEAFLET:**  
**Innovax-ILT concentrate and solvent for suspension for injection for chickens**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxtmeer  
THE NETHERLANDS

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Innovax-ILT concentrate and solvent for suspension for injection for chickens

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

Each dose (0.2 ml) of reconstituted vaccine contains:

Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus:  $10^{3.1} - 10^{4.1}$  PFU<sup>1</sup>.

<sup>1</sup> PFU: plaque forming units.

Concentrate and solvent for suspension for injection.

Cell concentrate: off-red to red cell concentrate.

Solvent: clear, red solution.

**4. INDICATION(S)**

For active immunization of one-day-old chicks to reduce mortality, clinical signs and lesions due to infection with avian infectious laryngotracheitis (ILT) virus and Marek's disease (MD) virus.

Onset of immunity:      ILT: 4 weeks,  
                                 MD: 9 days.

Duration of immunity:   ILT: 60 weeks,  
                                 MD: entire risk period.

**5. CONTRAINDICATIONS**

None.

**6. ADVERSE REACTIONS**

None known.

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Chickens.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

After dilution, administer 1 dose of 0.2 ml of vaccine per chicken by subcutaneous injection in the neck.

## **9. ADVICE ON CORRECT ADMINISTRATION**

The bag of vaccine should be gently swirled frequently during vaccination to guarantee that the vaccine suspension remains homogenous and that the correct vaccine virus titre is administered (e.g. during long vaccination sessions).

### Preparation of the vaccine:

Disinfect vaccinating equipment by boiling in water for 20 minutes or by autoclaving (15 minutes at 121 °C). Do not use chemical disinfectants.

The handling of liquid nitrogen should take place in a well-ventilated area.

1. Use solvent for cell associated poultry vaccines for reconstitution.  
For subcutaneous use reconstitute the vaccine according to the table below:

<b>Solvent bag</b>	<b>Number of vaccine ampoules for subcutaneous use</b>
Bag of 400 ml solvent	1 ampoule containing 2000 doses
Bag of 800 ml solvent	2 ampoules containing 2000 doses
Bag of 800 ml solvent	1 ampoule containing 4000 doses
Bag of 1200 ml solvent	3 ampoules containing 2000 doses
Bag of 1600 ml solvent	4 ampoules containing 2000 doses
Bag of 1600 ml solvent	2 ampoules containing 4000 doses

When this product is mixed with Nobilis Rismavac, both should be diluted in the same solvent bag in the same way (400 ml of solvent for each 2,000 doses of both products or 800 ml of solvent for each 4,000 doses of both products).

The solvent must be clear, red coloured, without sediment and at room temperature (15–25 °C) at the time of mixing

2. Preparation of the vaccine shall be planned before the ampoules are taken from the liquid nitrogen and the exact amount of vaccine ampoules and amount of solvent needed shall be calculated first. There is no information available on the number of doses on the ampoules once they are removed from the cane, so special care has to be taken to ensure that the mix-ups of ampoules with different number of doses is avoided and the correct solvent is used.
3. Before withdrawing the ampoules from the liquid nitrogen container, protect hands with gloves, wear long sleeves and use a facemask or goggles. When removing an ampoule from the cane, hold in the palm of a gloved hand away from the body and the face.
4. When withdrawing a cane of ampoules from the canister in the liquid nitrogen container, expose only the ampoule(s) to be used immediately. It is recommended to handle a maximum of 5 ampoules (from one cane only) at a time. After removing the ampoule(s), the remaining ampoules should be put back immediately into the canister in the liquid nitrogen container.
5. The content of the ampoule(s) is thawed rapidly by immersing in clean water at 25–27 °C. Gently swirl the ampoule(s) to disperse the contents. It is important that the ampoule content, after being thawed, is mixed immediately into the solvent to protect the cells. Dry the ampoule, then break the ampoule at its neck and immediately proceed as described below.
6. Gently withdraw the contents of the ampoule into a sterile syringe, mounted with an 18 gauge needle.

7. Insert the needle through the stopper of the solvent bag and add slowly and gently the contents of the syringe to the solvent. Gently swirl and invert the bag to mix the vaccine. Withdraw a portion of the solvent into the syringe to rinse the ampoule. Remove the washing from the ampoule and inject it gently into the solvent bag. Remove the syringe and invert the bag (6–8 times) to mix the vaccine.
8. The vaccine is now ready for use.

After adding the content of the ampoule to the solvent, the ready to use product is a clear, red coloured suspension for injection.

Control of correct storage:

To allow a check on correct storage and transport the ampoules are placed upside down in the liquid nitrogen containers. If frozen content is situated in the tip of the ampoule this indicates that the content has been thawed and must not be used.

## **10. WITHDRAWAL PERIOD(S)**

Zero days.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Cell concentrate: Store and transport frozen in liquid nitrogen (–196 °C).

Solvent: Store below 30 °C.

Container: Store liquid nitrogen container securely in upright position in a clean, dry and well-ventilated room separated from the hatching/chicken room in the hatchery.

Shelf life after reconstitution according to directions: 2 hours at a temperature below 25 °C.

## **12. SPECIAL WARNING(S)**

Special warnings for each target species:

Vaccinate healthy animals only.

Special precautions for use in animals:

As this is a live vaccine, the vaccine strain is excreted from vaccinated birds and may spread to turkeys. Safety trials have shown that the strain is safe for turkeys. However, precautionary measures have to be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys.

During subcutaneous vaccination, care should be taken to prevent damage of the blood vessels in the neck of the chickens.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

The handling of liquid nitrogen should take place in a well-ventilated area.

Innovax-ILT is a virus suspension packed in glass ampoules and stored in liquid nitrogen. Before withdrawing ampoules from the liquid nitrogen canister, use a personal protective equipment consisting of gloves, long sleeves and facemask and goggles. In case of an accident to prevent serious wounds by either the liquid nitrogen or the ampoules when removing an ampoule from the canister, hold palm of gloved hand away from body and face. Care should be exercised to prevent contaminating your hands, eyes and clothing with the ampoule content. CAUTION: Ampoules have been known to explode on sudden temperature changes. Do not thaw in hot or ice-cold water. For this reason, thaw the ampoules in clean water at 25–27 °C. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.



Fertility:

No information is available on use in future breeding birds.

Interaction with other medicinal products and other forms of interaction:

Safety and efficacy data are available which demonstrate that Innovax-ILT can be mixed in the same solvent and administered with Nobilis Rismavac in Member States where this vaccine is authorized. When Innovax-ILT is mixed with Nobilis Rismavac the development of immunity towards ILT may be delayed in animals with maternally derived antibodies.

For this mixed use, an onset of immunity of 5 days has been demonstrated for MD.

Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day, but not mixed with, Nobilis ND Clone 30 or Nobilis ND C2.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose (symptoms, emergency procedures, antidotes):

No symptoms were observed after the administration of a 10-fold dose of vaccine.

Incompatibilities:

Do not mix with any other veterinary medicinal product except Nobilis Rismavac and the solvent supplied for use with the veterinary medicinal product.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

{DD/MM/YYYY}

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency: (<http://www.ema.europa.eu/>).

**15. OTHER INFORMATION**

The vaccine is a cell-associated live recombinant turkey herpesvirus (HVT) expressing the gD and gI glycoproteins of infectious laryngotracheitis virus. The vaccine induces active immunity against infectious laryngotracheitis and Marek's disease in chickens.

Pack sizes:

1 ampoule, containing 2,000 or 4,000 doses. Ampoules are stored on a cane and attached to the cane is a coloured clip displaying the dose (2,000 doses: salmon-pink coloured clip, and 4,000 doses: yellow coloured clip).

Bag of 400 ml solvent, bag of 800 ml solvent, bag of 1200 ml solvent or bag of 1600 ml solvent.

Not all pack sizes may be marketed.